Evidence map›Paper›PMID 30729099›Full record

ArticleCanadian journal of gastroenterology & hepatology2019

Achieving Complete Remission of Hepatocellular Carcinoma: A Significant Predictor for Recurrence-Free Survival after Liver Transplantation.

Christin Bürger, Miriam Maschmeier, Anna Hüsing-Kabar, Christian Wilms, Michael Köhler, Martina Schmidt, Hartmut H Schmidt, Iyad Kabar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian journal of gastroenterology & hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Christin BürgerDepartment of Medicine B for Gastroenterology and Hepatology, University Hospital Muenster, 48149 Muenster, Germany.ORCID 0000-0003-2722-8366
Miriam MaschmeierDepartment of Medicine B for Gastroenterology and Hepatology, University Hospital Muenster, 48149 Muenster, Germany.ORCID 0000-0003-2008-0178
Anna Hüsing-KabarDepartment of Medicine B for Gastroenterology and Hepatology, University Hospital Muenster, 48149 Muenster, Germany.
Christian WilmsDepartment of Medicine B for Gastroenterology and Hepatology, University Hospital Muenster, 48149 Muenster, Germany.
Michael KöhlerDepartment of Clinical Radiology, University Hospital Muenster, 48149 Muenster, Germany.ORCID 0000-0002-1893-6072
Martina SchmidtDepartment of Medicine B for Gastroenterology and Hepatology, University Hospital Muenster, 48149 Muenster, Germany.
Hartmut H SchmidtDepartment of Medicine B for Gastroenterology and Hepatology, University Hospital Muenster, 48149 Muenster, Germany.
Iyad KabarDepartment of Medicine B for Gastroenterology and Hepatology, University Hospital Muenster, 48149 Muenster, Germany.ORCID 0000-0001-5132-3166

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Liver transplantation (LT) is a curative treatment for hepatocellular carcinoma (HCC) and the underlying primary liver disease; however, tumor recurrence is still a major issue. Therefore, the aim of this study was to assess predictors and risk factors for HCC recurrence after LT in patients within and outside the Milan criteria with a special focus on the impact of different bridging strategies. Methods: All patients who underwent LT for HCC between 07/2002 and 09/2016 at the University Hospital of Muenster were consecutively included in this retrospective study. Database research was performed and a multivariable regression analysis was conducted to explore potential risk factors for HCC recurrence. Results: A total of 82 patients were eligible for the statistical analysis. Independent of bridging strategy, achieving complete remission (CR) was significantly associated with a lower risk for tumor recurrence ( Conclusion: Achieving CR prior to LT results in a significant risk reduction of HCC recurrence after LT independent of the treatment modalities applied.

Indexed as

AgedCarcinoma, HepatocellularDisease-Free SurvivalFemaleHumansLiver NeoplasmsLiver TransplantationMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalRegression AnalysisRemission InductionRetrospective StudiesRisk Factors

Identifiers

PMID30729099
PMCPMC6341263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.